

# DIALOGUES

## I N C O N T R A C E P T I O N <sup>TM</sup>



### Post-Test

The following Post-Test contains 10 multiple-choice questions based on information contained in the *Dialogues in Contraception*<sup>TM</sup>, Volume 8, Number 6, newsletter. It is designed to enable practitioners to assess the knowledge they have gained from the newsletter and to identify areas for further study.

On the Answer Sheet, fill in all identifying information requested. Complete the Answer Sheet by circling, in each case, the one response that most accurately answers the question.

- Combination hormonal contraceptives are appropriate for otherwise healthy, nonsmoking women aged under 35 who have migraine without focal neurologic symptoms.
  - True
  - False
- The presence of which of the following is *not* a contraindication to use of combination hormonal contraceptives?
  - antiphospholipid antibodies
  - coronary artery disease
  - benign breast disease
  - smoking over age 35
- The World Health Organization (WHO) and the American College of Obstetricians and Gynecologists (ACOG) recommend routine screening for thrombophilic markers before prescribing OCs.
  - True
  - False
- Combination hormonal contraceptives are contraindicated in women with:
  - past history of gestational diabetes
  - diabetes and vascular disease
  - younger women with diabetes without vascular disease
  - all women with diabetes
- In women with underlying medical problems, the potential pregnancy-associated risks are greater than any associated with use of combination hormonal contraceptives.
  - True
  - False
- Ten years or more after discontinuation of OCs:
  - the relative risk for breast cancer diagnosis is greater in OC ever-users than in never-users
  - relative risk for breast cancer diagnosis is greater in OC past users than in current users
  - there is no difference in risk of breast cancer diagnosis between OC ever-users and never-users
  - cases diagnosed in past OC users are less likely to be localized to the breast than in never-users
- ACOG guidelines do not preclude OC use by healthy nonsmoking women with benign breast disease or a family history of breast cancer.
  - True
  - False
- The Cancer and Steroid Hormone (CASH) Study found that use of combination OCs protects against endometrial cancer, for at least \_\_\_ years after discontinuation.
  - 5
  - 15
  - 20
  - 30
- Ever-use of OCs, even as brief as 3 to 6 months, has been found to reduce risk of epithelial ovarian cancer by:
  - 20%
  - 30%
  - 40%
  - 50%
- OC use has been associated with reduced risk for:
  - colorectal cancer
  - liver cancer
  - breast cancer
  - cervical cancer

# DIALOGUES

## I N C O N T R A C E P T I O N <sup>TM</sup>



### Post-Test Answer Sheet

- |    |   |   |   |   |     |   |   |   |   |
|----|---|---|---|---|-----|---|---|---|---|
| 1. | a | b |   |   | 6.  | a | b | c | d |
| 2. | a | b | c | d | 7.  | a | b |   |   |
| 3. | a | b |   |   | 8.  | a | b | c | d |
| 4. | a | b | c | d | 9.  | a | b | c | d |
| 5. | a | b |   |   | 10. | a | b | c | d |

### CME or Nursing Contact Hour Enrollment

(PRINT)  
NAME \_\_\_\_\_ DEGREE \_\_\_\_\_  
FIRST LAST

MEDICAL LICENSE # \_\_\_\_\_ TELEPHONE NUMBER \_\_\_\_\_

ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

SPECIALTY \_\_\_\_\_ E-MAIL \_\_\_\_\_

#### METHOD OF PAYMENT

- Check (payable to USC or NPWH)  
 Credit Card

Visa/MasterCard # \_\_\_\_\_ Expiration Date \_\_\_\_\_

Authorized Signature \_\_\_\_\_ Amount \$ \_\_\_\_\_

To receive CME credit, please mail payment of \$15.00 or credit card information and this Answer Sheet to:

The Associate Dean, Office of Continuing Education, Keck School of Medicine of the University of Southern California  
1975 Zonal Avenue, KAM 317, Los Angeles, CA 90033-1039  
(323) 442-2555 or (800) USC-1119 – FAX (323) 442-2152 (for credit card payment only)

To receive nursing contact hours, please mail payment of \$15.00 or credit card information and this Answer Sheet to:

National Association of Nurse Practitioners in Women's Health  
503 Capitol Court NE, Suite 300, Washington, DC 20002  
(202) 543-9693 – FAX (202) 543-9858 (for credit card payment only)

# DIALOGUES

I N C O N T R A C E P T I O N <sup>TM</sup>



## Evaluation Questionnaire

We would appreciate your comments.  
Please return completed questionnaire to our toll-free fax number: (888) 665-8650.

1. How long did it take you to complete this CME activity? \_\_\_\_\_

2. I found the content (check appropriate boxes):

Not practical  Very practical

Moderately practical

Poorly written  Expertly written

Well written

Too difficult  Too easy

Moderately difficult

3. The stated objectives were achieved.  Yes  No

4. The examination questions were:

Too difficult  Too short  Poorly written

Too easy  Too long  Well written

5. Did you find the program:

Biased for or against any particular drug?  Yes  No

If yes, please explain: \_\_\_\_\_

\_\_\_\_\_

Fairly balanced in terms of treatment options?  Yes  No

If no, please explain: \_\_\_\_\_

\_\_\_\_\_

Suggestions for future topics: \_\_\_\_\_

\_\_\_\_\_

Additional comments: \_\_\_\_\_

\_\_\_\_\_

Name (optional): \_\_\_\_\_